Fitch Reaffirms Bristol-Myers Squibb Ratings

Fitch Ratings affirmed Bristol-Myers Squibb Co.’s ratings and said the outlook for the company remains “Stable,” citing moves by Bristol-Myers to offset the potential loss of future revenue as blockbuster drugs lose patent protection.
Forbes